Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer

State-of-the-Art Strategies for Targeting RET-Dependent Cancers

(2020) Vivek Subbiah et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

(2020) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

(2019) J Mazières et al.   ANNALS OF ONCOLOGY

A Phase 2 Study of Lenvatinib in Patients With RET Fusion-Positive Lung Adenocarcinoma

(2019) Toyoaki Hida et al.   LUNG CANCER

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

(2018) Alexander Drilon et al.   Cancer Discovery

Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial

(2017) Kiyotaka Yoh et al.   Lancet Respiratory Medicine

Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboringRETrearrangement: a phase II clinical trial

(2016) S.-H. Lee et al.   ANNALS OF ONCOLOGY

Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial

(2016) Alexander Drilon et al.   LANCET ONCOLOGY

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

(2014) Edward B Garon et al.   LANCET

Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitorsin vitroandin vivo

(2013) Makito Suzuki et al.   CANCER SCIENCE

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

(2012) Doron Lipson et al.   NATURE MEDICINE

KIF5B-RET fusions in lung adenocarcinoma

(2012) Takashi Kohno et al.   NATURE MEDICINE

RET, ROS1 and ALK fusions in lung cancer

(2012) Kengo Takeuchi et al.   NATURE MEDICINE

A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing

(2011) Y. S. Ju et al.   GENOME RESEARCH